| 1. |
- Fortier, A., et al.
(författare)
-
CHEOPS in-flight performance: A comprehensive look at the first 3.5 yr of operations
- 2024
-
Ingår i: Astronomy and Astrophysics. - 0004-6361 .- 1432-0746. ; 687
-
Tidskriftsartikel (refereegranskat)abstract
- Context. Since the discovery of the first exoplanet almost three decades ago, the number of known exoplanets has increased dramatically. By beginning of the 2000s it was clear that dedicated facilities to advance our studies in this field were needed. The CHaracterising ExOPlanet Satellite (CHEOPS) is a space telescope specifically designed to monitor transiting exoplanets orbiting bright stars. In September 2023, CHEOPS completed its nominal mission duration of 3.5 yr and remains in excellent operational conditions. As a testament to this, the mission has been extended until the end of 2026. Aims. Scientific and instrumental data have been collected throughout in-orbit commissioning and nominal operations, enabling a comprehensive analysis of the missiona's performance. In this article, we present the results of this analysis with a twofold goal. First, we aim to inform the scientific community about the present status of the mission and what can be expected as the instrument ages. Secondly, we intend for this publication to serve as a legacy document for future missions, providing insights and lessons learned from the successful operation of CHEOPS. Methods. To evaluate the instrument performance in flight, we developed a comprehensive monitoring and characterisation (M&C) programme. It consists of dedicated observations that allow us to characterise the instrumenta's response and continuously monitor its behaviour. In addition to the standard collection of nominal science and housekeeping data, these observations provide valuable input for detecting, modelling, and correcting instrument systematics, discovering and addressing anomalies, and comparing the instrumenta's actual performance with expectations. Results. The precision of the CHEOPS measurements has enabled the mission objectives to be met and exceeded. The satellitea's performance remains stable and reliable, ensuring accurate data collection throughout its operational life. Careful modelling of the instrumental systematics allows the data quality to be significantly improved during the light curve analysis phase, resulting in more precise scientific measurements. Conclusions. CHEOPS is compliant with the driving scientific requirements of the mission. Although visible, the ageing of the instrument has not affected the missiona's performance. The satellitea's capabilities remain robust, and we are confident that we will continue to acquire high-quality data during the mission extension.
|
|
| 2. |
- HARTMANN, O, et al.
(författare)
-
MU-SR STUDY OF CHARGE NEUTRALLY DOPED Y1-2XCAXTHXBA2CU3O7-DELTA
- 1994
-
Ingår i: PHYSICA C. - : ELSEVIER SCIENCE BV. - 0921-4534. ; 235, s. 1695-1696
-
Tidskriftsartikel (övrigt vetenskapligt/konstnärligt)abstract
- Muon spin relaxation measurements were performed on the Y1-2xCaxThxBa2Cu3O7-delta system covering the solubility range for doping in the orthorhombic phase. The low temperature relaxation rate was found to decrease with CaTh concentration in the dilute ra
|
|
| 3. |
- Lundqvist, P, et al.
(författare)
-
mu SR study of charge neutrally doped RE(1-2X)Ca(X)Pr(X)Ba(2)Cu(3)O(7-delta) (RE=Y, Nd)
- 1996
-
Ingår i: CZECHOSLOVAK JOURNAL OF PHYSICS. - : CZECHOSLOVAK JNL OF PHYSICS. - 0011-4626. ; 46, s. 1141-1142
-
Tidskriftsartikel (övrigt vetenskapligt/konstnärligt)abstract
- Pr substitution in the 123 superconductors lowers the critical temperature, T-c, drastically. Equal amounts of Ca and Pr were doped into the RE(1-2x)Ca(x)Pr(x)Ba(2)Cu(3)O(7-delta) superconductors (RE=Y, x less than or equal to 0.2 and Nd, x less than or e
|
|
| 4. |
|
|
| 5. |
|
|
| 6. |
|
|
| 7. |
- Lundqvist, P, et al.
(författare)
-
Neutron-diffraction studies and interatomic distances in Ca-Pr doped NdBa2Cu3O7-delta
- 1996
-
Ingår i: PHYSICA C. - : ELSEVIER SCIENCE BV. ; 269:3-4
-
Annan publikation (övrigt vetenskapligt/konstnärligt)abstract
- Sintered samples of Nd1-2xCaxPrxBa2Cu3O7-delta with x = 0, 0.025, 0.050, and 0.10 have been studied by electrical-resistivity measurements, X-ray and neutron diffraction and from calculated bond-valence sums (BVS). Doping of equal amounts of Ca-Pr suppre
|
|
| 8. |
|
|
| 9. |
|
|
| 10. |
- Zivkovic, AM, et al.
(författare)
-
Serum oxylipin profiles in IgA nephropathy patients reflect kidney functional alterations
- 2012
-
Ingår i: Metabolomics. - : Springer. - 1573-3882 .- 1573-3890. ; 8:6, s. 1102-1113
-
Tidskriftsartikel (refereegranskat)abstract
- Immunoglobulin A nephropathy (IgAN) is a leading cause of chronic kidney disease, frequently associated with hypertension and renal inflammation. ω-3 fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) in fish oil (FO) improve kidney function in animal models, but have inconsistent metabolic effects in humans. Oxylipin profiles in serum from IgAN patients supplemented with either FO or corn oil (CO) placebo were analyzed by liquid chromatography coupled to tandem mass spectrometry. EPA cyclooxygenase and lipoxygenase metabolites, and EPA and DHA epoxides and diols were increased in response to FO supplementation, as were total epoxides and epoxide/diol ratios. Several of these metabolites were drivers of separation as assessed by multivariate analysis of FO patients pre- vs. post-supplementation, including 17,18-dihydroxyeicosatrienoic acid, prostaglandin D3, prostagalandin E3, Resolvin E1, 12-hydroxyeicosapentaenoic acid, and 10(11)-epoxydocosapentaenoic acid. In patients whose proteinuria improved, plasma total oxylipins as well as several hydroxyoctadecadienoic acids, hydroxyeicosatetraenoic acids, and leukotriene B4 metabolites were among the metabolites that were significantly lower than in patients whose proteinuria either did not improve or worsened. These data support the involvement of oxylipins in the inflammatory component of IgAN as well as the potential use of oxylipin profiles as biomarkers and for assessing responsiveness to ω-3 fatty acid supplementation in IgAN patients.
|
|
